Ghent University Will Use Roche (RHHBY)'s LightCycler(R) 1536 Instrument in the Field of HT PCR for Cancer Research
4/20/2010 10:30:34 AM
PENZBERG, Germany--(BUSINESS WIRE)--Roche (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) and Ghent University (Belgium) have signed an agreement for the use of Roche's LightCycler® 1536 Instrument in various cancer research projects in Ghent. Studies include multigene expression signature profiling on cancer research samples and, digital PCR for sensitive detection of mutant cancer cells in a background of normal cells. Furthermore, DNA methylation analysis studies, copy number variant screening (CNV), and amplicon generation for next generation sequencing are part of the planned experiments. One potentially groundbreaking study is a qPCR based transcriptome-wide profiling, which represents a tremendous undertaking and novel approach in this research area. In a pilot experiment, Ghent University plans to measure all human genes in the four MAQC reference RNA samples.